Pharmacophore models for metabotropic 5-HT receptor ligands

Current Topics in Medicinal Chemistry

Volumn 6, Issue 18, 2006, Pages 2005-2026

  Bojarski, Andrzej J ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

3 D QSAR; 5 HT1 receptors; 5 HT2 receptors; 5 HT4 receptors; 5 HT6 receptors; 5 HT7 receptors; Pharmacophore models

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 METHOXY 3 (1,2,3,6 TETRAHYDRO 4 PYRIDYL) 1H INDOLE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ARALKYLAMINE; INDOLE DERIVATIVE; LYSERGIC ACID; METABOTROPIC RECEPTOR; METHYSERGIDE; METITEPINE; PHENYLALKYLAMINE; PIPERAZINE DERIVATIVE; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1B ANTAGONIST; SEROTONIN 1D AGONIST; SEROTONIN 2 AGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN 6 AGONIST; SEROTONIN 6 ANTAGONIST; SEROTONIN 7 AGONIST; SEROTONIN 7 ANTAGONIST; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR AFFECTING AGENT; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLMITRIPTAN;

CHEMICAL MODIFICATION; COMPARATIVE MOLECULAR FIELD ANALYSIS; DRUG BINDING SITE; DRUG CONFORMATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; MATHEMATICAL COMPUTING; MIGRAINE; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MODEL; PHARMACOPHORE; PHYSICAL CHEMISTRY; PILOT STUDY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEPTOR AFFINITY; REVIEW; STATISTICAL ANALYSIS; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

LIGANDS; MOLECULAR STRUCTURE; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33749506582     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606778522186     Document Type: Review

References (102)

1. Guner, O. F. History and evolution of the pharmacophore concept in computer-aided drug design. Curr. Top. Med. Chem. 2002, 2, 1321-1332.
2. Van Drie, J. H. Pharmacophore discovery - lessons learned. Curr. Pharm. Des 2003, 9, 1649-1664. 1
3. Pharmacophore Perception, Development and Use in Drug Design; Guner, O. F. Eds.; International University Line: La Jolla, CA., 2000.
4. Barnes, N. M.; Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38, 1083-1152.
5. Hoyer, D.; Hannon, J. P.; Martin, G. R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 2002, 71, 533-554.
6. Gaster, L. M.; King, F. D. Serotonin 5-HT3 and 5-HT4 receptor antagonists. Med. Res. Rev. 1997, 17, 163-214.
7. Morreale, A.; Iriepa, I.; Galvez, E. The 5-HT(3) and nACh ionotropic receptors: a perspective from the computational chemistry point of view. Curr. Med. Chem. 2002, 9. 99-125.
8. Li, Y.; Harte, W. E. A review of molecular modeling approaches to pharmacophore models and structure-activity relationships of ion channel modulators in CNS. Curr. Pharm. Des. 2002, 8, 99-110.
9. Cappelli, A.; Anzini, M.; Vomero, S.; Mennuni, L.; Makovec, F.; Hamon, M.; De Benedetti, P. G.; Menziani, M. C. The interactions of the 5-HT(3) receptor with arylpiperazine, tropane, and quinuclidine ligands. Curr. Top. Med. Chem. 2002, 2, 599-624.
10. Dukat, M. 5-HT3 serotonin receptor agonists: A Pharmacophoric Journey. Curr. Med. Chem. - Central Nervous System Agents, 2004, 4, 77-94.
11. Lopez-Rodriguez, M. L.; Ayala, D.; Benhamu, B.; Morcillo, M. J.; Viso, A. Arylpiperazine derivatives acting at 5-HT(1A) receptors. Curr. Med. Chem. 2002, 9, 443-469.
12. Westkaemper, R. B.; Glennon, R. A. Application of ligand SAR, receptor modeling and receptor mutagenesis to the discovery and development of a now class of 5-HT(2A) ligands. Curr. Top. Med. Chem. 2002, 2, 575-598.
13. Lopez-Rodriguez, M. L.; Benhamu, B.; Morcillo, M. J.; Murcia, M.; Viso, A.; Campillo, M.; Pardob, L. 5-HT(4) receptor antagonists: structure-affinity relationships and ligand-receptor interactions. Curr. Top, Med. Chem. 2002, 2, 625-641.
14. Langlois, M.; Fischmeister, R. 5-HT4 receptor ligands: applications and new prospects. J. Med. Chem. 2003, 46, 319-344.
15. Lopez-Rodriguez, M. L.; Benhamu, B.; Morcillo, M. J.; Porras, E.; Lavandera, J. L.; Pardo, L. Serotonin 5-HT7 Receptor Antagonists. Curr. Med. Chem. - Central Nervous System Agents 2004, 4, 203-214.
16. Chilmonczyk, Z. Models of 5-hydroxytryptamine receptors. A review. J. Pham. Pharmacol. 1995, 47, 791-801.
17. Lanfumey, L.; Hamon, M. 5-HT1 receptors. Curr. Drug Targets CNS Neurol. Disord. 2004, 3, 1-10.
18. Marshall, G. R., Barry, C. D., Bosshard, H. E., Dammkoehler, R. A., Dunn, D. A. The Conformational Parameter in Drug Design: The Active Analog Approach. In Computer-Assisted Drug Design; Olson, E. C. and Christofersen, R. E. Eds.; American Chemical Society: Washington, 1979; pp 205-226.
19. Hibert, M., Middlemiss, D. N., Fozard, J. R. The central 5-HT1A receptor: graphics computer-aided mapping of the agonist site. In Brain 5-HT1A receptors; Dourish, C. T., Ahlenius, S., and Huston, P. H. Eds.; Ellis Horwood: Chichester, 1987; pp 27-33.
20. Hibert, M. F.; McDermontt, I.; Middlemiss, D. N.; Mir, A. K.; Fozard, J. R. Radioligand binding study of a series of 5-HTIA receptor agonists and definition of a steric model of this site. Eur. J. Med. Chem. 1989, 24, 31-37.
21. Hilbert, M. F.; Gittos, M. W.; Middlemiss, D. N.; Mir, A. K.; Fozard, J. R. Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor. J. Med. Chem. 1988, 31, 1087-1093.
22. Sleight, A. J.; Peroutka, S. J. Identification of 5-hydroxytryptamine1A receptor agents using a composite pharmacophore analysis and chemical database screening. Naunyn Schmiedebergs Arch. Pharmacol. 1991, 343, 109-116.
23. Glennon, R. A., Westkaemper, R. B., Bartyzel, P. Medicinal Chemistry of Serotonergic Agents. In Serotonin Receptor Subtypes: Basic and Clinical Aspects; Peroutka, S. J. Ed.; Wiley-Liss, inc.: New York, 1991; pp 19-64.
24. Mellin, C.; Vallgarda, J.; Nelson, D. L.; Bjork, L.; Yu, H.; Anden, N. E.; Csoregh, I.; Arvidsson, L. E.; Hacksell, U. A 3-D model for 5-HT1A-receptor agonists based on stereoselective methyl-substituted and conformationally restricted analogues of 8-hydroxy-2-(dipropylamino) tetralin. J. Med. Chem. 1991, 34, 497-510.
25. Chidester, C. G.; Lin, C. H.; Lahti, R. A.; Haadsma-Svensson, S. R.; Smith, M. W. Comparison of 5-HT1A and dopamine D2 pharmacophores. X-ray structures and affinities of conformationally constrained ligands. J. Med. Chem 1993, 36, 1301-1315.
26. 1A Receptors. Bioorg. Med. Chem. 1995, 3, 533-538.
27. Chilmonczyk, Z.; Szelejewska-Wozniakowska, A.; Cybulski, J.; Cybulski, M.; Koziol, A. E.; Gdaniec, M. Conformational flexibility of serotonin 1A receptor ligands from crystallographic data. Updated model of the receptor pharmacophore. Arch. Pharm. (Weinheim) 1997, 330, 146-160.
28. Paluchowska, M. H.; Mokrosz, M. J.; Bojarski, A. J.; Wesolowska, A.; Borycz, J.; Charakchieva-Minol, S.; Chojnacka-Wójcik, E. On the bioactive conformation of NAN-190 (1) and MP3022 (2), 5-HT (1A) receptor antagonists. J. Med. Chem. 1999, 42, 4952-4960.
29. Perrone, R.; Berardi, F.; Colabufo, N. A.; Leopoldo, M.; Lacivita, E.; Tortorella, V.; Leonardi, A.; Poggesi, E.; Testa, R. trans-4-[4-(Methoxyphenyl) cyclohexyl]-1-arylpiperazines: a new class of potent and selective 5-HT(1A) receptor ligands as conformationally constrained analogues of 4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl) propyl]-1-arylpiperazine s. J. Med. Chem. 2001, 44, 4431-4442.
30. Cramer, R. D. I.; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
31. Jain, A. N.; Koile, K.; Chapman, D. Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark. J. Med. Chem. 1994, 37, 2315-2327.
32. Sprague, P. W. Automated Chemical Hypothesis Generation and Database Searching with Catalyst. In Petspetives in Drug Discovery and Design; De Novo Design; Müller, K. Eds; ESCOM Science Publishers B. V.: Leiden, 1995; pp 1-20.
33. El-Bermawy, M. A.; Lotter, H.; Glennon, R. A. Comparative molecular field analysis of the binding of arylpiperazines at 5-HT1A serotonin receptors. Med. Chem. Res. 1992, 2, 290-297.
34. Agarwal, A.; Pearson, P. P.; Taylor, E. W.; Li, H. B.; Dahlgren, T.; Herslof, M.; Yang, Y.; Lambert, G.; Nelson, D. L.; Regan, J. W. Three-dimensional quantitative structure-activity relationships of 5-HT receptor binding data for tetrahydropyridinylindole derivatives: a comparison of the Hansch and CoMFA methods. J. Med. Chem. 1993, 36, 4006-4014.
35. Langlois, M.; Bremont, B.; Rousselle, D.; Gaudy, F. Structural analysis by the comparative molecular field analysis method of the affinity of beta-adrenoreceptor blocking agents for 5-HT1A and 5-HT1B receptors. Eur. J. Pharmacol. 1993, 244, 77-87.
36. van Steen, B. J.; van Wijngaarden, I.; Tulp, M. T.; Soudijn, W. Structure-affinity relationship studies on 5-HT1A receptor ligands. 2. Heterobicyclic phenylpiperazines with H4-aralkyl substituents. J. Med. Chem. 1994, 37, 2761-2773.
37. Gaillard, P.; Carrupt, P. A.; Testa, B.; Schambel, P. Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models. J. Med. Chem. 1996, 39, 126-134.
38. Gaillard, P.; Carrupt, P. A.; Testa, B.; Boudon, A. Molecular lipophilicity potential, a tool in 3D QSAR: method and applications. J. Comput. Aided Mol. Des. 1994, 8, 83-96.
39. Lopez-Rodriguez, M. L.; Rosado, M. L.; Benhamu, B.; Morcillo, M. J.; Fernandez, E.; Schaper, K. J. Synthesis and structure-activity relationships of a new model of arylpiperazines. 2. Three-dimensional quantitative structure-activity relationships of hydantoin-phenylpiperazine derivatives with affinity for 5-HT1A and alpha 1 receptors. A comparison of CoMFA models. J. Med. Chem. 1997, 40, 1648-1656.
40. Lopez-Rodriguez, M. L.; Rosado, M. L.; Benhamu, B.; Morcillo, M. J.; Sanz, A. M.; Orensanz, L.; Beneitez, M. E.; Fuentes, J. A.; Manzanares, J. Synthesis and structure-activity relationships of a new model of arylpiperazines. 1.2- 4-(o-methoxyphenyl) piperazin-1-yl]methyl]- 1, 3-dioxoperhydroimidazo[1,5-alpha] pyridine: a selective 5-HT1A receptor agonist. J. Med. Chem. 1996, 39, 4439-4450.
41. 1A receptor ligands. Chemomet. Intell. Lab. Sys. 1999, 47, 239-252.
42. Martin, Y. C.; Bures, M. G.; Danaher, E. A.; DeLazzer, J.; Lico, I.; Pavlik, P. A. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. J. Comput. Aided Mol. Des 1993, 7, 83-102.
43. Jain, A. N.;.Harris, N. L.; Park, J. Y. Quantitative binding site model generation: compass applied to multiple chemotypes targeting the 5-HT1A receptor. J. Med. Chem. 1995, 38, 1295-1308.
44. Kurogi, Y.; Guner, O. F. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr. Med. Chem. 2001, 8, 1035-1055.
45. Orus, L.; Perez-Silanes, S.; Oficialdegui, A. M.; Martinez-Esparza, J.; Del Castillo, J. C.; Mourelle, M.; Langer, T.; Guccione, S.; Donzella, G.; Krovat, E. M.; Poptodorov, K.; Lasheras, B.; Ballaz, S.; Hervias, I.; Tordera, R.; Del Rio, J.; Monge, A. Synthesis and molecular modeling of new 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives with high affinity at the serotonin transporter and at 5-HT(1A) receptors. J. Med. Chem. 2002, 45, 4128-4139.
46. Lepailleur, A.; Bureau, R.; Paillet-Loilier, M.; Fabis, F.; Saettel, N.; Lemaitre, S.; Dauphin, F.; Lesnard, A.; Lancelot, J. C.; Rault, S. Molecular Modeling Studies Focused on 5-HT(7) versus 5-HT (1A) Selectivity. Discovery of Novel Phenylpyrrole Derivatives with High Affinity for 5-HT(7) Receptors. J. Chem. Inf. Model. 2005, 45, 1075-1081.
47. Slassi, A. Recent advances in 5-HT1B/1D receptor antagonists and agonists and their potential therapeutic applications. Curr. Top. Med. Chem. 2002, 2, 559-574.
48. Glen, R. C.; Martin, G. R.; Hill, A. P.; Hyde, R. M.; Woollard, P. M.; Salmon, J. A.; Buckingham, J.; Robertson, A. D. Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties. J. Med. Chem. 1995, 38, 3566-3580.
49. Moloney, G. P.; Robertson, A. D.; Martin, G. R.; MacLennan, S.; Mathews, N.; Dodsworth, S.; Sang, P. Y.; Knight, C.; Glen, R. A novel series of 2,5-substituted tryptamine derivatives as vascular 5HT1B/1D receptor antagonists. J. Med. Chem. 1997, 40, 2347-2362.
50. Moloney, G. P.; Garavelas, A.; Martin, G. R.; Maxwell, M.; Glen, R. C. Synthesis and serotonergic activity of variously substituted (3-amido)phenylpiperazine derivatives and benzothiophene-4-piperazine derivatives: novel antagonists for the vascular 5-HT1B receptor. Eur. J. Med. Chem. 2004, 39, 305-321.
51. 1D/1B serotonin receptor ligands. Med. Chem. Res. 2001, 10, 309-317.
52. Cottrell, S. J.; Gillet, V. J.; Taylor, R.; Wilton, D. J. Generation of multiple pharmacophore hypotheses using multiobjective optimisation techniques. J. Comput. Aided Mol. Des 2004, 18, 665-682.
53. Dukat, M.; Smith, C.; Herrick-Davis, K.; Teitler, M.; Glennon, R. A. Binding of tryptamine analogs at h5-HT1E receptors: a structure-affinity investigation. Bioorg. Med. Chem. 2004, 12, 2545-2552.
54. Holtje, H. D.; Briem, H. Theoretical Determinaton of the Putative Receptor-bound Conformations of 5-HT2 Receptor Agonists. Quant. Struct. -Act. Relat. 1991, 10, 193-197.
55. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857.
56. Holtje, H. D.; Jendretzki, U. K. Conformational analysis of 5-HT2 receptor antagonists. Pharm. Pharmacol. Lett. 1992, 1, 89-92.
57. Jendretzki, U. K.; Elz, S.; Holtje, H. D. Computer aided molecular analysis of 5-HT2A agonists. Pharm. Pharmacol. Lett. 1994, 3, 260-263.
58. Andersen, K.; Liljefors, T.; Gundertofte, K.; Perregaard, J.; Bogeso, K. P. Development of a receptor-interaction model for serotonin 5-HT2 receptor antagonists. Predicting selectivity with respect to dopamine D2 receptors. J. Med. Chem. 1994, 37, 950-962.
59. 2A Receptor Selectivity of Simple 1-(2-Pyrimidinyl)piperazine Derivatives. Pharmazie 1994, 49, 801-806.
60. 2A Receptor Ligands: A Verification of the Topographic Model. Arch. Pharm. (Weinheim) 1995, 328, 659-666.
61. Runyon, S. P.; Savage, J. E.; Taroua, M.; Roth, B. L.; Glennon, R. A.; Westkaemper, R. B. Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9, 10-dihydroanthracene. Bioorg. Med. Chem. Lett. 2001, 11, 655-658.
62. Westkaemper, R. B.; Runyon, S. P.; Savage, J. E.; Roth, B. L.; Glennon, R. A. Exploring the relationship between binding modes of 9-(aminomethyl)-9, 10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin receptor. Bioorg. Med. Chem. Lett. 2001, 11, 563-566.
63. Rowley, M.; Bristow, L. J.; Hutson, P. H. Current and novel approaches to the drug treatment of schizophrenia. J. Med. Chem. 2001, 44, 477-501.
64. Ravina, E.; Negreira, J.; Cid, J.; Masaguer, C. F.; Rosa, E.; Rivas, M. E.; Fontenla, J. A.; Loza, M. I.; Tristan, H.; Cadavid, M. I.; Sanz, F.; Lozoya, E.; Carotti, A.; Carrieri, A. Conformationally constrained butyrophenones with mixed dopaminergic (D(2)) and serotoninergic (5-HT(2A), 5-HT(2C)) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical antipsychotics. J. Med. Chem. 1999, 42, 2774-2797.
65. Baroni, M.; Constantino, G.; Cruciani, G.; Valigi, R.; Clementi, S. Generating Optimal Linear PLS Estimation (GOLPE): An Advanced Chemometric Tool for Handling 3D QSAR Problems. Quant. Struct. -Act. Relat. 1993, 12, 20
66. Brea, J.; Rodrigo, J.; Carrieri, A.; Sanz, F.; Cadavid, M. I.; Enguix, M. J.; Villazon, M.; Mengod, G.; Caro, Y.; Masaguer, C. F.; Ravina, E.; Centeno, N. B.; Carotti, A.; Loza, M. I. New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones. J. Med. Chem. 2002, 45, 54-71.
67. Klabunde, T.; Evers, A. GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects. Chembiochem. 2005, 6, 876-889.
68. Forbes, I. T.; Dabbs, S.; Duckworth, D. M.; Ham, P.; Jones, G. E.; King, F. D.; Saunders, D. V.; Blaney, F. E.; Naylor, C. B.; Baxter, G. S.; Blackburn, T. P.; Kennett, G. A.; Wood, M. D. Synthesis, biological activity, and molecular modeling of selective 5-HT(2C/2B) receptor antagonists. J. Med. Chem. 1996, 39, 4966-4977.
69. Bromidge, S. M.; Dabbs, S.; Davies, D. T.; Duckworth, D. M.; Forbes, I. T.; Ham, P.; Jones, G. E.; King, F. D.; Saunders, D. V.; Starr, S.; Thewlis, K. M.; Wyman, P. A.; Blaney, F. E.; Naylor, C. B.; Bailey, F.; Blackburn, T. P.; Holland, V.; Kennett, G. A.; Riley, G. J.; Wood, M. D. Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3- pyridylcarbamoyl)indolines. J. Med. Chem. 1998, 41, 1598-1612.
70. Joubert, L.; Hanson, B.; Barthet, G.; Sebben, M.; Claeysen, S.; Hong, W.; Marin, P.; Dumuis, A.; Bockaert, J. New sorting nexin (SNX27) and NHERF specifically interact with the 5-HT4a receptor splice variant: roles in receptor targeting. J. Cell Sci. 2004, 117, 5367-5379.
71. Buchheit, K. H.; Gamse, R.; Giger, R.; Hoyer, D.; Klein, F.; Kloppner, E.; Pfannkuche, H. J.; Mattes, H. The serotonin 5-HT4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site. J. Med. Chem. 1995, 38, 2326-2330.
72. Iskander, M. N.; Coupar, I. M.; Winkler, D. A. Investigation of 5-HT4 agonist activities using molecular field analysis. J. Chem. Soc., Perkin Trans. 2 1999, 2, 153-158.
73. Iskander, M. N.; Leung, L. M.; Buley, T.; Ayad, F.; Di, I. J.; Tan, Y. Y.; Coupar, I. M. Optimization of a pharmacophore model for 5-HT(4) agonists using CoMFA and receptor based alignment. Eur. J. Med. Chem. 2006, 41, 16-26.
74. Hibert, M. F.; Hoffmann, R.; Miller, R. C.; Carr, A. A. Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site. J. Med. Chem. 1990, 33, 1594-1600.
75. Lopez-Rodriguez, M. L.; Morcillo, M. J.; Benhamu, B.; Rosado, M. L. Comparative receptor mapping of serotoninergic 5-HT3 and 5-HT4 binding sites. J. Comput. Aided Mol. Des. 1997, 11, 589-599.
76. Lopez-Rodriguez, M. L.; Murcia, M.; Benhamu, B.; Viso, A.; Campillo, M.; Pardo, L. 3-D-QSAR/CoMFA and recognition models of benzimidazole derivatives at the 5-HT(4) receptor. Bioorg. Med. Chem. Lett. 2001, 11, 2807-2811.
77. Lopez-Rodriguez, M. L.; Murcia, M.; Benhamu, B.; Viso, A.; Campillo, M.; Pardo, L. Benzimidazole derivatives. 3. 3D-QSAR/CoMFA model and computational simulation for the recognition of 5-HT(4) receptor antagonists. J. Med. Chem. 2002, 45, 4806-4815.
78. Bureau, R.; Daveu, C.; Lemaitre, S.; Dauphin, F.; Landelle, H.; Lancelot, J. C.; Rault, S. Molecular design based on 3D-pharmacophore. Application to 5-HT4 receptor. J. Chem. Inf. Comput. Sci. 2002, 42, 962-967.
79. Nelson, D. 5-HT5 receptors. Curr. Drug Targets. CNS. Neurol. Disord. 2004, 3, 53-58.
80. Corbett, D. F.; Heightman, T. D.; Moss, S. F.; Bromidge, S. M.; Coggon, S. A.; Longley, M. J.; Roa, A. M.; Williams, J. A.; Thomas, D. R. Discovery of a potent and selective 5-ht(5A) receptor antagonist by high-throughput chemistry. Bioorg. Med. Chem. Lett. 2005, 15, 4014-4018.
81. Teitler, M.; Scheick, C.; Howard, P.; Sullivan III, J. E.; Iwamura, T.; Glennon, R. A. 5-HT5A serotonin receptor binding, a preliminary structure-activity investigation. Med. Chem. Res. 1997, 7, 207-218.
82. Glennon, R. A. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J. Med. Chem. 2003, 46, 2795-2812.
83. Doddareddy, M. R.; Cho, Y. S.; Koh, H. Y.; Pae, A. N. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists. Bioorg. Med. Chem. 2004, 12, 3977-3985.
84. Russell, M. G.; Baker, R. J.; Barden, L.; Beer, M. S.; Bristow, L.; Broughton, H. B.; Knowles, M.; McAllister, G.; Patel, S.; Castro, J. L. N-Arylsulfonylindole derivatives as serotonin 5-HT(6) receptor ligands. J. Med. Chem. 2001, 44, 3881-3895.
85. Doddareddy, M. R.; Lee, Y. J.; Cho, Y. S.; Choi, K. I.; Koh, H. Y.; Pae, A. N. Hologram quantitative structure activity relationship studies on 5-HT6 antagonists. Bioorg. Med. Chem. 2004, 12, 3815-3824.
86. Lopez-Rodriguez, M. L.; Benhamu, B.; de la, F. T.; Sanz, A.; Pardo, L.; Campillo, M. A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. J. Med. Chem. 2005, 48, 4216-4219.
87. Holenz, J.; Merce, R.; Diaz, J. L.; Guitart, X.; Codony, X.; Dordal, A.; Romero, G.; Torrens, A.; Mas, J.; Andaluz, B.; Hernandez, S.; Monroy, X.; Sanchez, E.; Hernandez, E.; Perez, R.; Cubi, R.; Sanfeliu, O.; Buschmann, H. Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands. J. Med. Chem. 2005, 48, 1781-1795.
88. Hedlund, P. B.; Sutcliffe, J. G. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol. Sci. 2004, 25, 481-486.
89. Leopoldo, M. Serotonin(7) receptors (5-HT(7)Rs) and their ligands. Curr. Med. Chem. 2004, 11, 629-661.
90. Lopez-Rodriguez, M. L.; Porras, E.; Benhamu, B.; Ramos, J. A.; Morcillo, M. J.; Lavandera, J. L. First pharmacophoric hypothesis for 5-HT7 antagonism. Bioorg. Med. Chem. Lett. 2000, 10, 1097-1100.
91. Lopez-Rodriguez, M. L.; Porras, E.; Morcillo, M. J.; Benhamu, B.; Soto, L. J.; Lavandera, J. L.; Ramos, J. A.; Olivella, M.; Campillo, M.; Pardo, L. Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives. J. Med. Chem. 2003, 46, 5638-5650.
92. Wilcox, R. E.; Ragan, J. E.; Pearlman, R. S.; Brusniak, M. Y.; Eglen, R. M.; Bonhaus, D. W.; Tenner, T. E. J.; Miller, J. D. High-affinity interactions of ligands at recombinant guinea pig 5HT7 receptors. J. Comput. Aided Mol. Des. 2001, 15, 883-909.
93. Vermeulen, E. S.; Schmidt, A. W.; Sprouse, J. S.; Wikstrom, H. V.; Grol, C. J. Characterization of the 5-HT(7) receptor. Determination of the pharmacophore for 5-HT(7) receptor agonism and CoMFA-based modeling of the agonist binding site. J. Med. Chem. 2003, 46, 5365-5374.
94. Snyder, J. P., Rao, S. N., Koehler, K. F., Vedani, A., Pellicciari, R. APOLLO Pharmacophores and the pseudoreceptor concept. In Trends in QSAR and Molecular Modeling; Wermuth, C. G. Ed.; ESCOM: Leiden, 1993; pp 44-51.
95. Krobert, K. A.; Levy, F. O. The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects. Br. J. Pharmacol. 2002, 135, 1563-1571.
96. Krobert, K. A.; Bach, T.; Syversveen, T.; Kvingedal, A. M.; Levy, F. O. The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution. Naunyn Schmiedebergs Arch. Pharmacol. 2001, 363, 620-632.
97. Lovell, P. J.; Bromidge, S. M.; Dabbs, S.; Duckworth, D. M.; Forbes, I. T.; Jennings, A. J.; King, F. D.; Middlemiss, D. N.; Rahman, S. K.; Saunders, D. V.; Collin, L. L.; Hagan, J. J.; Riley, G. J.; Thomas, D. R. A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-y1)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970). J. Med. Chem. 2000, 43, 342-345.
98. Vermeulen, E. S.; van Smeden, M.; Schmidt, A. W.; Sprouse, J. S.; Wikstrom, H. V.; Grol, C. J. Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides. J. Med. Chem. 2004, 47, 5451-5466.
99. Nordling, E.; Homan, E. Generalization of a targeted library design protocol: application to 5-HT7 receptor ligands. J. Chem. Inf. Comput. Sci. 2004, 44, 2207-2215.
100. Bureau, R.; Daveu, C.; Lancelot, J. C.; Rault, S. Molecular design based on 3D-pharmacophore. Application to 5-HT subtypes receptors. J. Chem. Inf. Comput. Sci. 2002, 42, 429-436.
101. Lepailleur, A.; Bureau, R.; Lemaitre, S.; Dauphin, F.; Lancelot, J. C.; Contesse, V.; Lenglet, S.; Delarue, C.; Vaudry, H.; Rault, S. Molecular design based on 3D pharmacophores. Applications to 5-HT7 receptors. J. Chem. Inf. Comput. Sci. 2004, 44, 1148-1152.
102. 1A receptor affinity in the group of long-chain arylpiperazine ligands. Bioorg. Med. Chem. Lett. 2004, 14, 5863-5866.